Search research articles
Contact Us
Filters
Showing results (121-130 of 179) with videos related to
Page
of 18
Sort By:
Blood
|
July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2022
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Kala Visvanathan, Leslie Cope, Mary Jo Fackler, et al.
JAMA Oncology
|
June 14, 2019
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak, Sara M Tolaney, Lee Schwartzberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
Anas Younes, Ajay K Gopal, Scott E Smith, et al.
The New England Journal of Medicine
|
November 1, 2018
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani, Ian Flinn, Leslie Popplewell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2016
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study
Kala Visvanathan, MaryJo S Fackler, Zhe Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 2, 2006
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology
Richard T Hoppe, Ranjana Hira Advani, Philip J Bierman, et al.
The Lancet. Oncology
|
May 9, 2016
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E Krop, Ingrid A Mayer, Vinod Ganju, et al.
Clinical Breast Cancer
|
August 14, 2010
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer
Andres Forero-Torres, Mansoor N Saleh, Janice A Galleshaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 179) with videos related to
Sort By:
Page
of 18
Blood
|
July 31, 2020
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L Bartlett, Alex F Herrera, Eva Domingo-Domenech, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 19, 2022
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial
Kala Visvanathan, Leslie Cope, Mary Jo Fackler, et al.
JAMA Oncology
|
June 14, 2019
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
Shaveta Vinayak, Sara M Tolaney, Lee Schwartzberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma
Anas Younes, Ajay K Gopal, Scott E Smith, et al.
The New England Journal of Medicine
|
November 1, 2018
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani, Ian Flinn, Leslie Popplewell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 22, 2016
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study
Kala Visvanathan, MaryJo S Fackler, Zhe Zhang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 2, 2006
Hodgkin disease/lymphoma. Clinical practice guidelines in oncology
Richard T Hoppe, Ranjana Hira Advani, Philip J Bierman, et al.
The Lancet. Oncology
|
May 9, 2016
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
Ian E Krop, Ingrid A Mayer, Vinod Ganju, et al.
Clinical Breast Cancer
|
August 14, 2010
Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer
Andres Forero-Torres, Mansoor N Saleh, Janice A Galleshaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2015
Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
Costanza Paoletti, Yufeng Li, Maria C Muñiz, et al.
Page
of 18